Gastric Ulcer Clinical Trial
Official title:
A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
The drug being tested in this study is called TAK-438. TAK-438 is being tested to treat people who have stomach ulcers and also may or may not have Helicobacter pylori (HP) infection. This study will look at stomach ulcer healing and also the elimination of HP in people who take TAK-438 versus lansoprazole. The study will enroll approximately 830 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need): - TAK-438 20 mg - Lansoprazole 30 mg Study treatment will depend upon the Helicobacter pylori infection status of the participant, and include bismuth-containing quadruple therapy for the first 2 weeks in H pylori infected (HP+) participants. HP+ participants will be asked to take a TAK- 438 tablet or a lansoprazole capsule twice daily in conjunction with bismuth-containing quadruple therapy for 2 weeks, followed up by a TAK-438 tablet or a lansoprazole capsule once daily for up to 6 weeks. HP- participants will be asked to take a TAK-438 tablet or a lansoprazole capsule once daily for up to 8 weeks. This multi-center trial will be conducted in China, Korea, Taiwan, and Philippines. The overall time to participate in this study is up to 12 weeks. Participants will make multiple visits plus final visit at 2 weeks or 4 weeks after last dose of study drug for a follow-up assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Completed |
NCT03291418 -
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05526339 -
HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
|
N/A | |
| Completed |
NCT01435525 -
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
|
N/A | |
| Terminated |
NCT00594854 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
|
Phase 3 | |
| Completed |
NCT00527787 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
| Completed |
NCT01129011 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
| Recruiting |
NCT05517408 -
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
|
N/A | |
| Recruiting |
NCT01946633 -
Remote-controlled Capsule Endoscopy: a Feasibility Study
|
N/A | |
| Completed |
NCT01964131 -
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT01150162 -
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT01037491 -
Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets
|
N/A | |
| Completed |
NCT00960869 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
| Completed |
NCT00961350 -
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
| Completed |
NCT00595517 -
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
|
Phase 3 | |
| Completed |
NCT00428701 -
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
|
Phase 4 | |
| Completed |
NCT01452711 -
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
|
Phase 3 | |
| Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
| Completed |
NCT02761512 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
|
Phase 3 | |
| Recruiting |
NCT03057171 -
A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA
|